Buyout + growth fund research profile
Everstone Capital is a private-markets platform investing across India and Southeast Asia through private equity, real estate and credit strategies, with a focus on building scaled businesses.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
Everstone Capital uses a buyout + growth approach across Consumer, health, services, industrial RE.
Current evidence
Everstone’s current private-equity disclosures identify Everstone Private Equity as a live Category II AIF and report more than $3.2 billion deployed across mid-market, control-growth and cross-border opportunities. Recent manager announcements document the 2025 Wingify acquisition and 2026 investments in Apothecon/Navinta and Qlar; the 2024 sustainability report documents MediaMint as a 2023 PE investment and reports ECP III/ECP IV portfolio evidence.
Strategy
Buyout + growth
Sector focus
Consumer, health, services, industrial RE
AIF structure context
Indian private equity, growth, buyout and many real-asset strategies are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
Everstone’s current private-equity disclosures identify Everstone Private Equity as a live Category II AIF and report more than $3.2 billion deployed across mid-market, control-growth and cross-border opportunities. Recent manager announcements document the 2025 Wingify acquisition and 2026 investments in Apothecon/Navinta and Qlar; the 2024 sustainability report documents MediaMint as a 2023 PE investment and reports ECP III/ECP IV portfolio evidence.
Investor questions
Everstone Capital is covered in Rupeia's private equity research universe. The current public record describes the strategy as Buyout + growth, with a sector focus of Consumer, health, services, industrial RE. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to Everstone Capital in the reviewed public sources: Apothecon, Navinta, Qlar, Wingify, MediaMint, Omega Healthcare, Apexon, API Holdings, Everlife, Slayback Pharma, Calibre, IndoStar. It does not represent a complete current portfolio unless the manager has published one.
Public records associate the platform with Burger King India’s IPO and IndoSpace’s logistics real-estate platform, alongside consumer, healthcare and industrial positions. A consolidated fund-level return is not disclosed here. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: The spreadsheet describes a $7B platform across private equity, IndoSpace real estate and credit history; this is platform-level scale, not a single current PE fund corpus.. Public terms or access information: Buyout and growth investing across consumer, healthcare, services and industrial real estate. Vehicle-level cheque and reserve terms are not consistently published.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Sameer Sain. Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review entry valuation, leverage, governance rights, concentration, execution of the value-creation plan and exit timing. The current open diligence point is: Final status of the latest PE vehicle and fund-level net returns remain not publicly disclosed. The prior mismatched Aavishkaar research trail is retained in legacyPublicSources..
2026-05-07: Everstone’s current private-equity disclosures identify Everstone Private Equity as a live Category II AIF and report more than $3.2 billion deployed across mid-market, control-growth and cross-border opportunities. Recent manager announcements document the 2025 Wingify acquisition and 2026 investments in Apothecon/Navinta and Qlar; the 2024 sustainability report documents MediaMint as a 2023 PE investment and reports ECP III/ECP IV portfolio evidence.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.